ERBB2 and breast cancer: For instance, the addition of pertuzumab, to the combination of the trastuzumab and docetaxel, was reported to prolong the long-term survival in patients with previously untreated metastatic HER2-positive BC (HR 0.69, 95% CI, 0.58 to 0.82) [11].